Non-Interventional Study to Evaluate Effect of Zoladex In EndometrioSIS (ESIS)

AstraZeneca

Status: Terminated

Conditions: Endometriosis

Study type: Observational

Funder types: Industry

Identifiers

NCT00761683

NIS-ORO-ZOL-2007/1

Details and patient eligibility

About

To observe the effect of goserelin 3,6mg sc depot injection by assessment of the mean percent reduction scores for symptoms: dysmenorrhoea, dyspareunia and pelvic pain; to observe the effect of goserelin 3,6mg sc depot injection by assessment of the mean percent reduction scores for pelvic tenderness and indurations; to observe the reduction in the proportion of patients requiring analgesics for the relief of pelvic pain for 6 months in patients treated with Zoladex 3.6 mg.

Enrollment: 105 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients diagnosed with endometriosis that the doctors have already decided to treat with Zoladex within the last month, before inclusion in this program, according to Romanian approved goserelin 3,6 mg

Exclusion criteria

• patients who have a known hypersensitivity to goserelin (Zoladex) or any of its excipients or any other GnRH analogue, pregnancy, according to Romanian approved goserelin 3,6 mg SmPC

Trial design

105 participants in 1 patient group

1

Description:

Patients diagnosed with endometriosis